Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients

N/ANot Yet RecruitingNCT07274345

Amira Mohamed Zidan2,000 enrolled

Overview

This study aims to determine the prevalence of antiviral drug resistance among Egyptian patients with chronic hepatitis B virus (HBV) infection and to identify the associated demographic, clinical, and virological risk factors. Understanding patterns of resistance will help improve treatment selection and optimize long-term management strategies for HBV patients.

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

Chronic Hepatitis B - Antiviral Drug Resistance - Hepatitis B Virus (HBV) Infection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * This study will include all chronic HBV-infected patients, either cirrhotic or not, receiving TDF 300 mg, ETV 0.5 or 1mg, or lamivudine 100 mg, irrespective of HBeAg status. The HBV chronicity is defined by persistence of HbsAg positivity for more than 6 months. Exclusion Criteria: * Patients younger than 18 years old.

Outcomes

Primary Outcomes

Proportion of Patients Exhibiting Antiviral Resistance Detection of HBV Antiviral Resistance Mutations

Time frame: 6 months

Central Contacts

Amira Mohamed Zidan

CONTACT

201122884060 amira_mohamed_post@med.sohag.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.